Human monoclonal antibody against TGF-β type II...

Details Human monoclonal antibody against TGF-β type II... Human monoclonal antibody against TGF-β type II...

2000-11-17

2009-08-25

Allen, Marianne P (Department: 1647)

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

C530S388100, C530S388150, C530S388220

Reexamination Certificate

active

07579186

ABSTRACT:
Various human monoclonal antibodies that bind to human TGF-β type II receptor to inhibit the signal transduction of human TGF-β signal into cells are produced by immunizing human antibody-producing transgenic mice generated by genetic engineering techniques with the soluble human TGF-β type II receptor. Further, these human monoclonal antibodies were demonstrated to be effective for preventing and treating various diseases induced by human TGF-β in various organs (for example, tissue fibrosis).

REFERENCES:
patent: 5147798 (1992-09-01), Lampkin et al.
patent: 5693607 (1997-12-01), Segarini et al.
patent: 5824655 (1998-10-01), Border
patent: 6037139 (2000-03-01), Greenspan et al.
patent: 6096878 (2000-08-01), Honjo et al.
patent: 6201108 (2001-03-01), Lin et al.
patent: WO 91/10741 (1991-07-01), None
patent: WO 94/26895 (1994-11-01), None
patent: WO 01/66140 (2001-09-01), None
Muda, A. et al. Nephrol. Dial. Transplant. (1998), vol. 13, pp. 279-284.
Alberts et al. Molecular Biology of the Cell, 1989, pp. 1013-1014.
Hall et al. Biochem. J. 1996, vol. 316, pp. 303-310.
Peters et al., Kidney Int. 1998 54(5), pp. 1570-1580.
Herrera, G. Kidney Internat. 40:509-513, 1991 ‘C-erb B-2 amplification in cystic renal disease’.
Cao, Y. et al. “TGF-β1 Mediates 70-kDa Heat Shock Protein Induction due to Ultraviolet Irradiation in Human Skin Fibroblasts”Eur. J. Physiol.438:239-44 (1999).
Lagadec, P. et al. “Evidence for Control of Nitric Oxide Synthesis by Intracellular Transforming Growth Factor- β1 in Tumor Cells”Amer. J. Path.154:1867-76 (1999).
Kasuga, H. et al. “Effects of Anti-TGF-beta Type II Receptor Antibody on Experimental Glomerulonephritis”Kidney Int.60:1745-55 (2001).
European Search Report for EP 00976330, dated Jun. 4, 2004.
Rudikoff et al. “Single amino acid substitution altering antigen-binding specificity.”Proc. Natl. Acad. Sci. USA79:1979-1983 (1982).
Border et al., “Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta1,” Nature 346:371-374 (Jul. 26, 1990).
Brown et al., “Antibodies to the Type II TGF Beta Receptor Block Cell Activation and Migration during Atrioventricular Cushion Transformation in the Heart,”Developmental Biology174:248-257 (1996).
Fortunel et al., “Release from Quiescence of Primitive Human Hematopoietic Stem-Progenitor Cells by Blocking Their Surface TGF-Beta Type II Receptor in a Short-Term In Vitro Assay”Stem Cells, 18:102-111 (2000).
Meikle et al., “Transforming Growth Factor Beta-1 and Beta-2 and Type II Receptor Functional Regulation of ALVA-101 Human Prostate Cancer Cells,”Metabolism, 48(9):1075-1081 (1999).
Moustakas et al., “The Transforming Growth Factor Beta Receptors Types I, II and III Form Hetero-oligomeric Complexes in the Presence of Ligand,”J. Biol. Chem., 268(30):22215-22218 (1993).
George, et al., “In vivo inhibition of rat stellate cell activation by soluble transforming growth factor β type II receptor: A potential new therapy for hepatic fibrosis”,PNAS, (Oct. 26, 1999) 96(22):12719-12724.

Affiliated with

Also associated with

Rating

Human monoclonal antibody against TGF-β type II... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Human monoclonal antibody against TGF-β type II..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human monoclonal antibody against TGF-β type II... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4126300